(PETS) PetMed Express - Ratings and Ratios
Medications, Supplements, Hygiene, Supplies
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 63.3% |
| Value at Risk 5%th | 85.0% |
| Relative Tail Risk | -18.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -51.00 |
| CAGR/Max DD | -0.50 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.708 |
| Beta | 1.073 |
| Beta Downside | 1.238 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.37% |
| Mean DD | 68.20% |
| Median DD | 78.74% |
Description: PETS PetMed Express December 27, 2025
PetMed Express Inc. (NASDAQ:PETS) operates a U.S.-focused online pet pharmacy that sells both prescription and over-the-counter medications, health products, and ancillary pet supplies for dogs, cats, and horses. Sales are fulfilled through its website, mobile app, a call-center, and direct-mail marketing, with the company headquartered in Delray Beach, Florida, and incorporated in 1996.
Key recent metrics (FY 2023): revenue of $1.05 billion, a 7 % year-over-year increase driven primarily by higher prescription-drug volumes and a 12 % rise in average order value; gross margin improved to 38 % from 35 % in 2022 as the mix shifted toward higher-margin generics; and net loss of $45 million, reflecting continued investment in logistics and marketing. The pet-pharmacy market is expanding at roughly 9 % CAGR, propelled by the “humanization” of pets and growing veterinary prescription-drug utilization, while e-commerce penetration in pet supplies is now above 45 % of total spend.
Sector drivers that materially affect PETS include (1) overall pet-care spending, which the American Pet Products Association projects to exceed $120 billion in 2025; (2) regulatory trends around veterinary telehealth and e-prescribing, which could lower customer acquisition costs; and (3) competitive pressure from large e-retailers such as Chewy and 1-800-Pets, which intensifies price competition and necessitates differentiation through formulary breadth and fulfillment speed.
For a deeper, data-rich analysis of PETS’ valuation assumptions and scenario modeling, you may find the free tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -41.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -26.51 > 1.0 |
| NWC/Revenue: 1.33% < 20% (prev 7.14%; Δ -5.80% < -1%) |
| CFO/TA -0.27 > 3% & CFO -27.5m > Net Income -41.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.9m) vs 12m ago -0.25% < -2% |
| Gross Margin: 28.37% > 18% (prev 0.25%; Δ 2812 % > 0.5%) |
| Asset Turnover: 164.5% > 50% (prev 177.3%; Δ -12.81% > 0%) |
| Interest Coverage Ratio: -24.79 > 6 (EBITDA TTM -2.56m / Interest Expense TTM 326.0k) |
Altman Z'' 0.97
| A: 0.03 (Total Current Assets 59.5m - Total Current Liabilities 56.7m) / Total Assets 100.3m |
| B: 0.24 (Retained Earnings 23.9m / Total Assets 100.3m) |
| C: -0.06 (EBIT TTM -8.08m / Avg Total Assets 126.5m) |
| D: 0.42 (Book Value of Equity 23.9m / Total Liabilities 57.2m) |
| Altman-Z'' Score: 0.97 = BB |
Beneish M -3.69
| DSRI: 1.13 (Receivables 1.97m/2.26m, Revenue 208.1m/270.8m) |
| GMI: 0.90 (GM 28.37% / 25.40%) |
| AQI: 0.38 (AQ_t 0.12 / AQ_t-1 0.31) |
| SGI: 0.77 (Revenue 208.1m / 270.8m) |
| TATA: -0.14 (NI -41.1m - CFO -27.5m) / TA 100.3m) |
| Beneish M-Score: -3.69 (Cap -4..+1) = AAA |
ValueRay F-Score (Strict, 0-100) 17.25
| 1. Piotroski: 2.50pt |
| 2. FCF Yield: -90.88% |
| 3. FCF Margin: -15.55% |
| 4. Debt/Equity: 0.02 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -19.02% |
| 7. RoE: -57.17% |
| 8. Revenue Trend: -57.80% |
| 9. EPS Trend: -51.75% |
What is the price of PETS shares?
Over the past week, the price has changed by -0.61%, over one month by -5.76%, over three months by +22.93% and over the past year by -29.98%.
Is PETS a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PETS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.8 | -15.1% |
| Analysts Target Price | 2.8 | -15.1% |
| ValueRay Target Price | 2.3 | -30.2% |
PETS Fundamental Data Overview January 27, 2026
P/S = 0.3578
P/B = 1.6478
P/EG = 2.58
Revenue TTM = 208.1m USD
EBIT TTM = -8.08m USD
EBITDA TTM = -2.56m USD
Long Term Debt = 768.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 477.0k USD (from shortTermDebt, last quarter)
Debt = 768.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.3m USD (from netDebt column, last quarter)
Enterprise Value = 35.6m USD (70.9m + Debt 768.0k - CCE 36.1m)
Interest Coverage Ratio = -24.79 (Ebit TTM -8.08m / Interest Expense TTM 326.0k)
EV/FCF = -1.10x (Enterprise Value 35.6m / FCF TTM -32.4m)
FCF Yield = -90.88% (FCF TTM -32.4m / Enterprise Value 35.6m)
FCF Margin = -15.55% (FCF TTM -32.4m / Revenue TTM 208.1m)
Net Margin = -19.73% (Net Income TTM -41.1m / Revenue TTM 208.1m)
Gross Margin = 28.37% ((Revenue TTM 208.1m - Cost of Revenue TTM 149.1m) / Revenue TTM)
Gross Margin QoQ = 27.98% (prev 28.14%)
Tobins Q-Ratio = 0.36 (Enterprise Value 35.6m / Total Assets 100.3m)
Interest Expense / Debt = 42.45% (Interest Expense 326.0k / Debt 768.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.38m (EBIT -8.08m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.05 (Total Current Assets 59.5m / Total Current Liabilities 56.7m)
Debt / Equity = 0.02 (Debt 768.0k / totalStockholderEquity, last quarter 43.1m)
Debt / EBITDA = 13.81 (negative EBITDA) (Net Debt -35.3m / EBITDA -2.56m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -35.3m / FCF TTM -32.4m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.45% (Net Income -41.1m / Total Assets 100.3m)
RoE = -57.17% (Net Income TTM -41.1m / Total Stockholder Equity 71.8m)
RoCE = -11.13% (EBIT -8.08m / Capital Employed (Equity 71.8m + L.T.Debt 768.0k))
RoIC = -8.89% (negative operating profit) (NOPAT -6.38m / Invested Capital 71.8m)
WACC = 10.12% (E(70.9m)/V(71.7m) * Re(9.87%) + D(768.0k)/V(71.7m) * Rd(42.45%) * (1-Tc(0.21)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
Fair Price DCF = unknown (Cash Flow -32.4m)
EPS Correlation: -51.75 | EPS CAGR: -10.63% | SUE: 0.24 | # QB: 0
Revenue Correlation: -57.80 | Revenue CAGR: -10.55% | SUE: 4.0 | # QB: 1
EPS current Year (2026-03-31): EPS=-0.22 | Chg30d=-0.100 | Revisions Net=-1 | Growth EPS=+26.7% | Growth Revenue=-12.3%
EPS next Year (2027-03-31): EPS=0.01 | Chg30d=+0.090 | Revisions Net=+1 | Growth EPS=+104.6% | Growth Revenue=+3.0%
Additional Sources for PETS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle